SI3231801T1 - Bipirazolna sol kot inhibitor JAK - Google Patents

Bipirazolna sol kot inhibitor JAK

Info

Publication number
SI3231801T1
SI3231801T1 SI201431118T SI201431118T SI3231801T1 SI 3231801 T1 SI3231801 T1 SI 3231801T1 SI 201431118 T SI201431118 T SI 201431118T SI 201431118 T SI201431118 T SI 201431118T SI 3231801 T1 SI3231801 T1 SI 3231801T1
Authority
SI
Slovenia
Prior art keywords
bipyrazole
salt
jak inhibitor
jak
inhibitor
Prior art date
Application number
SI201431118T
Other languages
English (en)
Inventor
Yun-Long Li
Jincong Zhuo
Ding-Quan Qian
Song Mei
Ganfeng Cao
Yongchun Pan
Qun Li
Zhongjiang Jia
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of SI3231801T1 publication Critical patent/SI3231801T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SI201431118T 2013-05-17 2014-05-16 Bipirazolna sol kot inhibitor JAK SI3231801T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17
EP17158350.3A EP3231801B1 (en) 2013-05-17 2014-05-16 Bipyrazole salt as jak inhibitor

Publications (1)

Publication Number Publication Date
SI3231801T1 true SI3231801T1 (sl) 2019-05-31

Family

ID=50983151

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201431754T SI3527263T1 (sl) 2013-05-17 2014-05-16 Derivati bipirazola kot zaviralci JAK
SI201431118T SI3231801T1 (sl) 2013-05-17 2014-05-16 Bipirazolna sol kot inhibitor JAK
SI201430239A SI2997023T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot inhibitorji JAK
SI201432046T SI3786162T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci JAK

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201431754T SI3527263T1 (sl) 2013-05-17 2014-05-16 Derivati bipirazola kot zaviralci JAK

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI201430239A SI2997023T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot inhibitorji JAK
SI201432046T SI3786162T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci JAK

Country Status (35)

Country Link
US (6) US9382231B2 (sl)
EP (5) EP4275756A3 (sl)
JP (4) JP6415543B2 (sl)
KR (3) KR102341908B1 (sl)
CN (2) CN107698569B (sl)
AR (2) AR096330A1 (sl)
AU (5) AU2014265279B2 (sl)
BR (1) BR112015028501B8 (sl)
CA (1) CA2911536C (sl)
CL (1) CL2015003355A1 (sl)
CR (2) CR20190156A (sl)
CY (3) CY1119105T1 (sl)
DK (3) DK3231801T3 (sl)
EA (2) EA039660B1 (sl)
ES (4) ES2626793T3 (sl)
FI (1) FI3786162T3 (sl)
HK (2) HK1221466A1 (sl)
HR (4) HRP20231048T1 (sl)
HU (4) HUE063817T2 (sl)
IL (4) IL242453B (sl)
LT (4) LT2997023T (sl)
ME (2) ME03355B (sl)
MX (2) MX2020004506A (sl)
MY (1) MY174788A (sl)
PE (2) PE20160126A1 (sl)
PH (2) PH12015502563A1 (sl)
PL (3) PL2997023T3 (sl)
PT (4) PT3786162T (sl)
RS (4) RS61482B1 (sl)
SG (2) SG11201509180WA (sl)
SI (4) SI3527263T1 (sl)
TR (1) TR201905814T4 (sl)
TW (3) TW202116320A (sl)
UA (1) UA117830C2 (sl)
WO (1) WO2014186706A1 (sl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
KR101549876B1 (ko) 2007-06-13 2015-09-03 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
NZ596374A (en) 2009-05-22 2014-01-31 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
BRPI1015135B1 (pt) 2009-06-29 2021-08-03 Incyte Holdings Corporation Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI3050882T1 (sl) 2010-03-10 2018-06-29 Incyte Holdings Corporation Derivati piperidin-4-il azetidina, kot inhibitorji JAK1
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
UA120834C2 (uk) 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Лікарські форми руксолітинібу зі сповільненим вивільненням
CA3091179C (en) 2013-03-06 2023-01-17 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
CN106456773A (zh) * 2014-02-28 2017-02-22 因赛特公司 用于治疗骨髓增生异常综合征的jak1抑制剂
US10064866B2 (en) 2014-04-08 2018-09-04 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
CA2947418A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
CR20170389A (es) 2015-02-27 2018-01-26 Incyte Corp Sales de inhibidor de p13k y procesos de preparación
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
BR112019004486A2 (pt) * 2016-09-06 2019-05-28 Hoffmann La Roche compostos de 8-(azetidin-1-il)-[1,2,4] triazolo [1,5a] piridinil, composições e métodos de uso dos mesmos
CR20200214A (es) 2017-10-18 2020-07-25 Incyte Corp ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
US11103510B2 (en) 2018-02-16 2021-08-31 Incyte Corporation JAK1 pathway inhibitors for the treatment of cytokine-related disorders
EP3775284A1 (en) 2018-03-30 2021-02-17 Incyte Corporation Biomarkers for inflammatory skin disease
SG11202009441PA (en) * 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
WO2019200030A1 (en) * 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
DK3847175T3 (da) 2018-09-05 2024-03-18 Incyte Corp Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
SG11202104321PA (en) 2018-10-31 2021-05-28 Incyte Corp Combination therapy for treatment of hematological diseases
CN113692278A (zh) 2018-12-19 2021-11-23 因赛特公司 用于治疗胃肠道疾病的jak1途径抑制剂
MX2021010545A (es) 2019-03-05 2021-11-17 Incyte Corp Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
WO2020191041A2 (en) 2019-03-19 2020-09-24 Incyte Corporation Biomarkers for vitiligo
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CA3157499A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230027086A (ko) 2020-06-02 2023-02-27 인사이트 코포레이션 Jak1 저해제의 제조 공정
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2023539126A (ja) 2020-08-18 2023-09-13 インサイト・コーポレイション Ｊａｋ阻害剤を調製するための方法及び中間体
EP4200278A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
US20220202834A1 (en) 2020-12-04 2022-06-30 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases
KR20230118118A (ko) 2020-12-08 2023-08-10 인사이트 코포레이션 백반증의 치료를 위한 jak1 경로 저해제
CN114081889A (zh) * 2020-12-29 2022-02-25 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
CA3219092A1 (en) 2021-05-03 2022-11-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5646749A (en) * 1979-09-26 1981-04-28 Mitsui Toatsu Chemicals Protective sheet for surface
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
JP4456365B2 (ja) 2001-09-19 2010-04-28 アベンティス・ファーマ・ソシエテ・アノニム 化合物
ATE335490T1 (de) 2001-10-30 2006-09-15 Novartis Pharma Gmbh Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR101549876B1 (ko) 2007-06-13 2015-09-03 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
BRPI0820544A2 (pt) * 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
EP2288610B8 (en) * 2008-03-11 2016-10-12 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
NZ596374A (en) 2009-05-22 2014-01-31 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN102596960B (zh) 2009-10-09 2016-01-20 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
CA2790070C (en) 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
SI3050882T1 (sl) 2010-03-10 2018-06-29 Incyte Holdings Corporation Derivati piperidin-4-il azetidina, kot inhibitorji JAK1
CN102985424B (zh) * 2010-04-14 2015-03-11 阵列生物制药公司 5,7-取代的-咪唑并[1,2-c]嘧啶
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
SG192910A1 (en) 2011-02-24 2013-09-30 Massachusetts Inst Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013043962A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
TW201406761A (zh) * 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
UA120834C2 (uk) 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Лікарські форми руксолітинібу зі сповільненим вивільненням
CA3091179C (en) 2013-03-06 2023-01-17 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
UA117830C2 (uk) 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
TW201512193A (zh) 2013-05-17 2015-04-01 Hoffmann La Roche 用於治療及防治ｂ型肝炎病毒感染之新穎６－橋聯雜芳基二氫嘧啶
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
CN106456773A (zh) 2014-02-28 2017-02-22 因赛特公司 用于治疗骨髓增生异常综合征的jak1抑制剂
CA2947418A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9549916B2 (en) 2014-12-16 2017-01-24 Novartis Ag Isoxazole hydroxamic acid compounds as LpxC inhibitors
KR20230027086A (ko) 2020-06-02 2023-02-27 인사이트 코포레이션 Jak1 저해제의 제조 공정
US20220202834A1 (en) 2020-12-04 2022-06-30 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases

Also Published As

Publication number Publication date
EP2997023B9 (en) 2018-06-13
AU2014265279A1 (en) 2015-11-26
US11591318B2 (en) 2023-02-28
SI3527263T1 (sl) 2021-05-31
NZ713999A (en) 2020-11-27
EP3786162B1 (en) 2023-08-09
BR112015028501A2 (pt) 2017-07-25
EA036448B1 (ru) 2020-11-11
ME03355B (me) 2019-10-20
MX2015015738A (es) 2016-03-16
KR102341908B1 (ko) 2021-12-23
IL287313A (en) 2021-12-01
KR20160019905A (ko) 2016-02-22
RS64591B1 (sr) 2023-10-31
RS56012B1 (sr) 2017-09-29
SG10201709469SA (en) 2017-12-28
HUE053122T2 (hu) 2021-06-28
CA2911536A1 (en) 2014-11-20
EA039660B1 (ru) 2022-02-24
AU2020202000A1 (en) 2020-04-09
KR20210120120A (ko) 2021-10-06
MY174788A (en) 2020-05-14
AU2022263454B2 (en) 2024-01-18
RS58743B1 (sr) 2019-06-28
HRP20231048T1 (hr) 2023-12-22
RS61482B1 (sr) 2021-03-31
HUE033587T2 (hu) 2017-12-28
EP2997023A1 (en) 2016-03-23
CN105452239B (zh) 2017-11-21
PL3527263T3 (pl) 2021-05-17
US20200010456A1 (en) 2020-01-09
NZ753637A (en) 2020-11-27
PH12018502125A1 (en) 2019-03-25
JP6775560B2 (ja) 2020-10-28
ES2720073T3 (es) 2019-07-17
US11905275B2 (en) 2024-02-20
KR102442747B1 (ko) 2022-09-14
PE20160126A1 (es) 2016-02-24
LT3231801T (lt) 2019-08-12
DK3231801T3 (en) 2019-04-15
HUE063817T2 (hu) 2024-01-28
PL2997023T3 (pl) 2017-08-31
US20180312492A1 (en) 2018-11-01
CN107698569A (zh) 2018-02-16
CY1123756T1 (el) 2022-05-27
ES2626793T3 (es) 2017-07-26
CL2015003355A1 (es) 2016-05-27
DK3786162T3 (da) 2023-10-09
EP4275756A2 (en) 2023-11-15
US20210238168A1 (en) 2021-08-05
JP7126741B2 (ja) 2022-08-29
US9926301B2 (en) 2018-03-27
US9382231B2 (en) 2016-07-05
US20230159501A1 (en) 2023-05-25
HRP20210119T1 (hr) 2021-03-05
KR20220127371A (ko) 2022-09-19
IL282644B (en) 2021-10-31
AU2021202685B2 (en) 2022-11-17
PH12015502563B1 (en) 2016-02-22
SI2997023T1 (sl) 2017-07-31
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
CN107698569B (zh) 2020-11-27
PE20200527A1 (es) 2020-03-09
NZ753639A (en) 2020-11-27
CN105452239A (zh) 2016-03-30
CA2911536C (en) 2021-07-20
ES2960731T3 (es) 2024-03-06
EP3527263A1 (en) 2019-08-21
JP2019011364A (ja) 2019-01-24
IL282644A (en) 2021-06-30
ES2845210T3 (es) 2021-07-26
AU2021202685A1 (en) 2021-05-27
EP4275756A3 (en) 2024-02-07
BR112015028501B1 (pt) 2022-11-01
EP3231801A1 (en) 2017-10-18
EP3527263B1 (en) 2020-10-28
ME02763B (me) 2018-01-20
AU2018223058A1 (en) 2018-09-20
UA117830C2 (uk) 2018-10-10
NZ753636A (en) 2020-11-27
HRP20190713T1 (hr) 2019-06-14
IL264409A (en) 2019-02-28
PT2997023T (pt) 2017-05-31
WO2014186706A1 (en) 2014-11-20
PT3231801T (pt) 2019-05-24
HRP20170795T1 (hr) 2017-08-25
TWI664176B (zh) 2019-07-01
TWI719401B (zh) 2021-02-21
FI3786162T3 (fi) 2023-10-02
IL287313B (en) 2022-03-01
CY1121763T1 (el) 2020-07-31
BR112015028501B8 (pt) 2023-01-24
PT3786162T (pt) 2023-10-20
AU2020202000B2 (en) 2021-03-11
CY1119105T1 (el) 2018-02-14
EA201592199A1 (ru) 2016-05-31
LT2997023T (lt) 2017-06-26
JP6415543B2 (ja) 2018-10-31
US10435392B2 (en) 2019-10-08
PH12015502563A1 (en) 2016-02-22
AR118120A2 (es) 2021-09-22
AU2018223058B2 (en) 2020-01-02
JP2016519147A (ja) 2016-06-30
NZ753638A (en) 2020-11-27
TW202116320A (zh) 2021-05-01
TW201512191A (zh) 2015-04-01
CR20190156A (es) 2019-05-16
HK1221466A1 (zh) 2017-06-02
EA202090291A3 (ru) 2020-06-30
AR096330A1 (es) 2015-12-23
SI3786162T1 (sl) 2024-02-29
CR20150633A (es) 2016-04-05
LT3527263T (lt) 2021-05-10
PT3527263T (pt) 2021-02-01
HK1245769B (zh) 2020-02-07
AU2014265279B2 (en) 2018-09-27
JP2021008493A (ja) 2021-01-28
US11001571B2 (en) 2021-05-11
US20160289215A1 (en) 2016-10-06
US20140343030A1 (en) 2014-11-20
EP3231801B1 (en) 2019-02-13
EP2997023B1 (en) 2017-03-22
HUE043573T2 (hu) 2019-08-28
IL242453B (en) 2019-11-28
EP3786162A1 (en) 2021-03-03
SG11201509180WA (en) 2015-12-30
IL264409B (en) 2021-05-31
DK3527263T3 (da) 2021-01-25
AU2022263454A1 (en) 2022-12-08
MX2020004506A (es) 2021-08-09
JP2022163162A (ja) 2022-10-25
TR201905814T4 (tr) 2019-05-21
EA202090291A2 (ru) 2020-05-31
TW201940479A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
HK1245769B (zh) 作為jak抑制劑的聯吡唑鹽
HK1216531A1 (zh) 新的抑制劑
GB201304526D0 (en) New compounds
ZA201506296B (en) 2-acylaminothiazole derivative or salt thereof
GB201317609D0 (en) Inhibitor compounds
GB201304527D0 (en) New compounds
IL240763B (en) The halopyrazoles as thrombin inhibitors
IL245452B (en) Salts of Armachol
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201305945D0 (en) New compounds
GB201304773D0 (en) New compounds
GB201304777D0 (en) New compounds
GB201304780D0 (en) New compounds
GB201304782D0 (en) New compounds